Nov. 10 at 3:17 PM
Nektar Therapeutics announced new data showing that its experimental drug, rezpegaldesleukin, improved asthma symptoms in patients with atopic dermatitis. The data, presented at the American College of Allergy, Asthma, and Immunology Annual Scientific Meeting, showed statistically significant improvements in asthma control questionnaire scores at week 16 compared to placebo in patients with both atopic dermatitis and asthma. The findings came from the ongoing Phase 2b REZOLVE-AD study of the first-in-class IL-2 pathway agonist developed by Nektar.
Patients treated with rezpegaldesleukin showed more pronounced improvements if they had partially controlled or uncontrolled asthma at the start of the study. In patients with uncontrolled asthma, all three dosing regimens achieved statistical significance compared to placebo, with 75% of patients in the highest dose group (24 μg/kg every two weeks) experiencing clinically significant improvement.
$NKTR